Conference Day Two |
Thursday, September 25, 2025

7:30 am Morning Coffee & Registration

8:20 am Chairs Opening Remarks

Aligning Regulatory Expectations with Process Development & CMC Requirements to Accelerate mRNA Platform Advancement

8:30 am Fireside Chat: Bridging Regulatory Gaps in Manufacturing of Cancer Vaccines in Clinical Phases: Aligning Process Development & CMC to Achieve GMP Certification & Tech Transfer Readiness

Synopsis

NEW COMPANY

NOVEL MRNA MODALITY

Download the Full Event Guide to see the session details 

9:30 am Designing the Ideal mRNA Platform: How to Align with CEPI’s Vision for Rapid Outbreak Response

10:00 am Morning Break

Track 1: Research Scale

Enhancing mRNA Stability to Extend Shelf Life, Improve Translation, & Support Global Distribution

11:00 am Leveraging Identity Assays to Enhance Drug Substance Stability to Preserve Integrity & Extend Usability Across Development Stages

Christine Tkaczyk, Director, AstraZeneca

11:30 am Achieving Thermostability Through Lyophilization to Extend Shelf Life & Improve Storage Flexibility

Brian Luk, Senior Scientist II, Arcturus Therapeutics

12:00 pm Harnessing Modifications to Enhance Drug Product Stability & Reduce Cold Chain Burden

Manasa Chilara, Researcher - Todd Przybycien Lab, Rensselaer Polytechnic Institute
Track 2: IND Enabling & Clinical Scale

12:30 pm Lunch Break

Track 1: Research Scale

Evolving Formulation Strategies to Improve Stability, Delivery Precision & Modality Compatibility for Increased Patient Use

1:30 pm Engineering Next-Generation LNP Design to Maximise Payload, Encapsulation Efficiency & Mechanistic Understanding

Daryl Drummond, Chief Scientific Officer, Akagera Medicines

2:00 pm Reimagining RNA Delivery: Breaking the LNP Barrier with Peptide-Based Vectors

Gilles Divita, Chief Executive Officer, Divincell

2:30 pm Exploring Non-Lipid-Based Nanoparticles to Expand Delivery and Storage Options to Improve Patient Accessibility

Kinkini Roy, Associate Director, Drug Product Development, Aviceda Therapeutics
Track 2: IND Enabling & Clinical Scale

3:00 pm Afternoon Break

Executing Commercial Manufacturing with Robust Supply & Regulatory Frameworks to Increase Market Penetration & Global Reach

3:30 pm Roundtable: Building Globally Resilient Supply Chains to Support mRNA Vaccine & Therapeutic Commercialization

4:00 pm Leading the Way in Self-Amplifying RNA: Commercialization of saRNA Vaccine Manufacturing

  • Charles Cabral Senior Director - Manufacturing Science & Technology, Arcturus Therapeutics

4:30 pm End of Conference